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comparative effectiveness and economics information to better inform decision 
making in the evaluation of new health technologies. The impact of comparative 
effectiveness research and economics on formulary decision making will likely have 
more impact in the future. If study data are to be considered valuable in supporting 
health care decision-making, the rigor, transparency, and the customer perspective 
needs to drive the study methods and designs.
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OBJECTIVES: Post-hoc subgroup analyses are still used in clinical trials of medi-
cal technologies to identify patient populations in whom greatest benefits can 
be achieved, despite this being derided as an analytical approach. Indeed, using 
post-hoc analyses, aspirin has been shown to be ineffective in acute myocardial 
infarction patients born under the star signs of Libra and Gemini (ISIS-2, 1988, 
Lancet) and endarterectomy is only efficacious in treating symptomatic steno-
sis patients born on a Monday, Wednesday, or Friday (ECST group, 1998, Lancet). 
This research aimed to determine whether National Institute of Health and Care 
Excellence (NICE) appraisal recommendations could be correlated with full moon 
dates through application of a post-hoc analysis. METHODS: All NICE final appraisal 
determinations were identified up to October 2014 from which the date and deci-
sion was extracted. Full moon dates for Manchester were extracted from www.
timeanddate.com. Statistical comparisons were performed using a Chi-squared 
test. RESULTS: 532 appraisals were identified, 408 (77%) of which were approved 
(defined as ‘recommended’ or ‘optimised’). However, among the 38 recommenda-
tions issued ±1 day of a full moon this recommendation rate significantly rose to 
89% (34/38, p< 0.05). Significantly fewer appraisals also occurred in the 14-day period 
bisected by full moons versus the 14-day period bisected by new moons (183 vs. 359, 
p< 0.0001). CONCLUSIONS: Based on our post-hoc analysis, the NICE committee are 
unduly afraid of werewolves leading them being less productive around the period 
of a full moon. However, if they are pushed to issue a final recommendation close to 
a full moon they will more likely issue a positive recommendation. As werewolves 
are afraid of running water, the feasibility of constructing a moat around the NICE 
headquarters should be explored. Alternatively, regulators and HTA bodies should 
continue to view efficacy claims on the basis of post-hoc sub-group analyses with 
great scepticism.
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OBJECTIVES: To identify the predictors of the nurses undergoing a Compliance 
Monitoring Program (CMP) for substance/drug abuse successfully and assessing the 
effect of these variables on the successful completion of program. METHODS: This 
was a retrospective cross-sectional cohort study using the de-identified data from 
the Florida Intervention Project for Nurses (IPN). Status of CMP program categorized 
as ‘completed’ and ‘Incomplete’ formed the dependent variable. The independent 
variables were characteristics of the nurses - demographic (education, marital sta-
tus), type of treatment employed, years of nursing experience, healthcare institu-
tional setting that employed the nurses, healthcare specialty of nurses, diagnostic 
and statistical manual of mental disorders (DSM-axes), lab results for presence of 
drugs, presence of substance related disorders (dependency, abuse), family history 
of biological, non-biological and mental diseases, lab test results during relapse, if 
aftercare is required at end of program, status of treatment at end of program, type 
of contract, reason for dismissal from program and whether individual treatment 
is required. Imputation procedures using the Markov chain Monte Carlo simulation 
with maximum-likelihood estimation were employed to fill missing data. Statistical 
tests included descriptive analysis including chi-square tests followed by logistic 
regression (p< 0.05). RESULTS: All independent variables except family history of 
mental diseases were found associated with the status of the CMP. The stepwise 
logistic regression yielded only nursing experience in years, type of healthcare insti-
tution, specialty, nursing license and treatment (all p< 0.0001) were found associ-
ated with the completion of the CMP at p< 0.05. CONCLUSIONS: Nursing profession 
characteristics like healthcare setting, specialty and years of experience seemed to 
have a higher association with completion of the CMP for substance abuse.
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OBJECTIVES: Since July 2012, a new therapy may be allocated Breakthrough Therapy 
status if it a) treats a serious and life-threatening condition, and b) preliminary 
evidence suggests substantial clinical improvement over existing therapies based 
on a clinically meaningful endpoint. For such agents, the FDA will expedite their 
development and review. This research aimed to systematically analyse all therapies 
have been approved under this new FDA expedited review pathway. METHODS: All 
publically available FDA documents relating to the approval of therapies under a 
breakthrough status were extracted up to 28th November 2014 and their date, drug 
type, and supportive trial package were extracted. RESULTS: The FDA has approved 
14 therapeutic agents designated as breakthrough therapies (to 1st December 2014), 
7 oncologics, 6 non-oncologics and 1 vaccine. 6/14 also simultaneously received FDA 
accelerated approval. 9 submissions were first approvals whereas 5 were line exten-
sions. 7 of these submissions were based on Phase 3 trial data, 5 on phase 2, and 2 
on phase 1 data. The average review time from submission to approval was 181 days 
(range: 126 – 242 days). There appeared no correlation between review times and 
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OBJECTIVES: The breakthrough therapy pathway provides an expedited Food and 
Drug Administration (FDA) review where preliminary clinical evidence suggests 
potentially substantial clinical improvement for a serious, life-threatening condi-
tion. This has enabled regulatory approval on data packages as early as Phase 1 data 
(ceritinib and pembrolizumab.) We wanted to research the question of whether 
such clinical data would be sufficient for US payer coverage. METHODS: On 5th 
December 2014, publically available benefits documents were extracted from 3 
national (AETNA, Anthem, and United Healthcare [UHC]) and 1 regional (Rocky 
Mountain) insurance companies for the 14 therapies approved by the FDA under 
this pathway. The coverage status, prior authorisation criteria, and price were 
compared. RESULTS: Most of the 14 FDA-approved drugs under the Breakthrough 
Therapy designation were covered by these insurers (AETNA: 10/14, UHC: 10/14, 
Anthem: 9/14, Rocky Mountain: 7/14). Most instances of drugs not covered reflect 
those approved very recently. However, the majority were subject to prior authori-
zations (AETNA: 10/10, Anthem: 9/9, UHC: 5/10, Rocky Mountain: 7/7). These prior 
authorizations sometimes included clinical criteria more stringent than those in the 
FDA label (15/31 similar to FDA label, 9/31 slightly more restrictive, 7/31 much more 
restrictive). The drugs most frequently subject to much greater restrictions than the 
FDA label were Sovaldi and Harvoni. The level of restrictions were not seemingly 
related to the patient cost per treatment which ranged up to $307,000 (Kalydeco) but 
rather seemed correlated with budget impact (very large with Sovaldi and Harvoni, 
indicated for Hepatitis C). CONCLUSIONS: Breakthrough status can result in early 
US payer approval in addition to regulatory approval. Insurers may place additional 
restrictions through prior authorizations but this relates more to the budget impact 
of the drugs than the cost per patient or level of supportive clinical evidence.
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OBJECTIVES: The US is the largest prescription drug market in the world, charac-
terised by high drug prices internationally with traditionally few price controls. 
This sustainability of the largely free-pricing of pharmaceuticals has long been 
questioned against the background of increasing pharmaceutical spend. The recent 
market entrants of innovative Hepatitis C virus (HCV) therapies with potentially 
substantial budgetary implications have driven US public and private payers to 
implement a range of cost-containment mechanisms. This research aims to com-
pare these new changes with European processes and predict how the future 
pricing and reimbursement (P&R) landscape will evolve in the US. METHODS: A 
thematic analysis of P&R changes and activities in the US December 2013-January 
2015 was undertaken, with the outcomes analysed in the context of European P&R 
processes. RESULTS: The range of novel cost-control mechanisms in the US includes 
major pharmacy benefits management organisations (CVS and Express Scripts) 
agreeing exclusivity deals with a particular HCV drug manufacturer, based on the 
most competitively priced. Further, the California Technology Assessment Forum, 
which had only previously evaluated one drug in its 13 year history, has undertaken 
already one review of HCV therapies (with another one ongoing) recommending 
restricting SOVALDI and OLYSIO to the most severe patients based on a cost-utility 
analysis. Further, under Medicaid, nearly half of all states have restricted SOVALDI 
beyond the FDA-approved label. CONCLUSIONS: Cost-control mechanisms in the US 
have started to reshape the P&R landscape with European-style price competition, 
restricting drugs to subpopulations beyond the label, and cost-effectiveness analy-
ses utilisation now starting to take hold. As pharmaceutical spend continues to grow, 
such cost-management tools will become further embedded in a wider variety of 
US payers. With variable usage of distinct cost-containment tools by different payer 
bodies, the US payer landscape will likely increasingly resemble that of Europe.
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OBJECTIVES: To identify United States (US) decision maker perceptions of data from 
observational studies and other health economics and outcomes research in the 
evaluation of emerging health technologies. METHODS: We conducted qualitative 
one-on-one interviews with payers (5), clinicians (6), and hospital administrators 
(4) in the US to determine perceptions of data collected outside of randomized con-
trolled trials in the evaluation of emerging health technologies. RESULTS: Clinical 
efficacy and safety postmarketing assessments have more of an impact on decision 
making than other types of study data collected outside clinical trials. Compared 
with other stakeholders, clinicians placed a particularly high value on patient reg-
istries, whereas, hospital administrators placed a high value on budget-impact 
analysis. Annual/semiannual review of drug classes by health plans and hospital 
formulary committees may include patient registry data; however, these data typi-
cally are not available when a new health technology is first introduced into the 
market. Real-world outcomes and head-to-head comparisons are highly desirable, 
but were also the most commonly mentioned data gaps in evaluating new health 
technologies. Clinicians more commonly sought data that affect patient treatment 
decisions, confidence in prescribing, and subpopulation data. Payers and hospital 
administrators were interested in real-world outcomes data in their specific patient 
populations, and data that could have an impact on costs, cost offsets, resource utili-
zation, and readmissions. CONCLUSIONS: Stakeholders in the US are seeking more 
A76  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  
letters containing 655 violations for 204 drugs across multiple therapeutic areas 
were issued by the FDA all of which were clinical. Most often multiple violations 
for > 1 drug were contained in a single letter. On average, ~36 warning letters 
were issued per year. Omission of risk information was the most frequently viola-
tion claim (29.0%) followed by unsubstantiated/overstatement of efficacy claims 
(24.76%), and broadening of indication (11.6%). There were no misleading QoL, or 
economic claims issued. Warning letters were primarily directed to manufactur-
ers of oncology (17.5%), psychiatry (9.6%), cardiovascular (9.6%), and pain (8.8%) 
products. Approximately half (49.5%) of claims contained promotional materials 
directed to physicians. CONCLUSIONS: We found that misleading clinical outcome 
claims, specifically omission of risk information and inaccurate efficacy, formed 
the majority of the promotional violations. Compared to the preceding 6 years 
(2003-2008), substantially more FDA warning letters were issued (65 vs 178) pos-
sibly indicating greater surveillance by the FDA of pharmaceutical promotional 
materials 2009-2013.
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OBJECTIVES: In Egypt, the Ministry of Health and Population (MOHP) sets phar-
maceutical prices from ex-factory to retail. In July 2012, the pricing policy changed 
from a cost plus to an external reference pricing method which was effective in 
October 2012. Our goal was to identify the characteristics of products with price 
changes after the policy implementation. Methods: We used MOHP lists and IMS 
data to pre-identify products with price changes. METHODS: We used MOHP lists 
and IMS data to pre-identify products with price changes. In addition, purchase 
and sales data were obtained from a chain pharmacy in Alexandria for all trans-
actions pre- and post- the policy change (April - Jun 2012 and 2013) to validate 
price changes, assess sales activity, and identify any additional products with 
price changes. Bivariate analysis and a logistic regression model were done to 
identify the determinants of price increase or decrease per Daily Defined Dose 
(DDD). RESULTS: A total of 206 products were subject to price changes; 66% of the 
products had price increase, 70% were generics, 36% were essential drugs, 40% 
of the products had prices less than 1EGP[1]/DDD, 30% were between1 and 5EGP/
DDD and 30% were higher than 5EGP/DDD. Half of the products were produced 
by domestic private companies, 27% by multinational firms, 21% by state-owned 
companies and 2% were imported. The products of state-owned firms had 23 times 
the odds of the products of multinational firms to have a price increase. Similarly, 
the cheapest products had 9 times the odds of a price increase compared to high 
priced products. Compared to brand name drugs, generics had 6.8 times the likeli-
hood of a price increase. CONCLUSIONS: Being the product of State-owned firms, 
a product whose price was ≤ 1EGP/DDD or a generic were the main determinants 
of price increase. [1] 1 EGP= $0.14 USD
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OBJECTIVES: The healthcare profile in sub-Saharan Africa is changing due to eco-
nomic growth, an increasing middle class, urbanization, and rising incidence of 
non-communicable diseases. These factors increase demand for medications. 
Pharmaceutical spending in the region is projected to reach $45 billion by 2016. 
Despite this rapid growth and gap between availability and demand, companies 
have yet to initiate local pharmaceutical manufacturing due to the challenges of 
doing business in the region. We report on a framework to assess these challenges 
and feasibility of overcoming them. METHODS: We undertook a series of key stake-
holder interviews in Namibia, including distribution, private sector, regulatory, and 
governmental representatives. Namibia had virtually no drug manufacturing at 
time of assessment despite political will to undertake manufacturing. RESULTS: 
In-country pharmaceutical manufacturing is viewed as important for health and 
economic development and stability. Key areas identified for concern included 
product selection, education, training, quality control, perceptions of quality, sup-
ply chain, role of public and private sectors, and market demand. Creation of a 
facility at the local university was recommended to build public trust, enhance 
training, and facilitate distribution. Product areas for initial consideration may 
include sterile water/saline, alcohol hand rub, oral preparations, topical prepara-
tions, total parenteral nutrition, or cancer chemotherapy. CONCLUSIONS: In order 
to create a sustainable health care system in sub-Saharan Africa, local pharmaceu-
tical manufacturing will be necessary to provide a consistent supply of medicine. 
Product selection is of key importance to match local demand and be reasonably 
competitive economically. Viable choices could be niche products or large volume 
generics. Regulatory and quality concerns will have to be thoroughly addressed to 
establish a successful system. Technical expertise will have to be increased and 
maintained. Overall, if concerns are addressed early and thoroughly, local manu-
facturing could provide increase political and economic stability in sub-Saharan 
Africa while improving health.
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OBJECTIVES: Considerable attention is given to managing opioid use in order to 
avoid addiction and possible diversion problems. A Pharmacy Quality Alliance work-
group has been working on a pharmacy quality measure where morphine equivalent 
the level of supportive clinical data (Phase 1: a mean of 158 days, Phase 2: 170 days, 
Phase 3: 196 days), whether the drug was a first approval or line extension (175 vs. 
192 days), or whether it was approved under an accelerated FDA pathway or not (172 
vs. 184 days) CONCLUSIONS: The FDA breakthrough therapy designation is proving 
a popular means by which promising drugs can gain patient access on preliminary 
data packages from as little as Phase I supportive data. However, although this 
pathway has enabled earlier access, it does not speed the required review times 
with the average of 6 month review being in line with FDA priority review targets.
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OBJECTIVES: This study analyzes the influence of intellectual property rights pro-
tection on the profile of drug request by litigation in the Health Department of 
Minas Gerais state (SES-MG), Brasil, the public spending and its interfaces with 
the rational use of drugs and the incorporation of new technologies in the Unified 
Health System (SUS). METHODS: This is a descriptive observational study of litiga-
tion by drugs attended by SES-MG. There were analyzed 4,140 records of lawsuits 
in 2010 attended by SES-MG and 1,065 rulings published in the website of the Court 
of Minas Gerais State, in the period from 2007 to 2009. RESULTS: In 2010, SES-MG 
attended 28,104 prescriptions requirement of legalization, the average being 2.2 
medications per patient. The prevalence of polypharmacy was 10.6%. In addition 
to individual lawsuits, the SES-MG attended 19 civil suits which included 135 medi-
cines. The ten most demanded drugs were protected by patents. Of these, only 
three were included on the list of essential medicines. For all products there were 
prescriptions by brand name, an average of 50% of the requests had required supply 
trademark. The survey indicated a prevalence of jurisprudential injunction and the 
use of prescription drugs cited as evidence, without medical expertise. Ensuring the 
constitutional right to health was the speech used in more shares. It was observed 
that the lawsuits are at odds with the rational use of medicines recommended by 
World Health Organization (WHO). CONCLUSIONS: The annual expense to ensure 
access to medicines for litigation is growing and represents a major challenge for 
the public manager. The high prevalence of new medicines prescribed by trademark 
and growth of biological drug prescriptions show the need to review and strengthen 
the policy of generic drugs in Brazil.
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OBJECTIVES: To analyze how main determinants of competition in six therapeutic 
target groups -analgesics, tranquilizers, peptic ulcer treatment, cholesterol treat-
ment, benign prostatic hypertrophy and ACE inhibitors- were affected by regula-
tions and drug policies implemented at national level during the last decade in 
the pharmaceutical market in Argentina. METHODS: The database corresponds 
to the annual information on retail sales in the Argentine pharmaceutical sector 
generated by IMS for the period 2005-2012. The estimation strategy takes the form 
of econometric models of ordinary least squares with year fixed effects and robust 
standard errors. The dependent variables explain the market shares of each product/
brand per therapeutic class, explained by prices, participant active principles, and 
a set of variables capturing product differentiation mechanisms implemented by 
pharmaceutical firms. Each therapeutic class’ regression was exposed to a vector of 
variables capturing the structure of the regulatory framework. RESULTS: In general, 
prices do not show to be significant determinants of market shares, unlike factors 
associated with mechanisms of product differentiation do, proving they facilitate 
the development of brand loyalty and adherence, even with relatively higher prices. 
On the other hand, the inclusion of new active principles in the Compulsory Health 
Program (CHP) will act as a boost for priority prescriptions, while the production 
of generic medicines increases competition, reducing market shares. In addition, 
the impact of these policies rests heavily on the structure of competition in each 
therapeutic class. CONCLUSIONS: The main health policy recommendations sug-
gest: the need to develop new areas of collaboration with the pharmaceutical sector, 
enhancing competition in markets with higher levels of concentration, facilitating 
the evaluation of policies on generic medicines, and successfully regularizing the 
structure of drugs and products available through the CHP.
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OBJECTIVES: While analyses of FDA warning letters issues to pharmaceutical 
companies for misleading promotional outcomes claims have been published for 
1997-2008 (Stewart 2002; Salas 2008; Covington, 2009; Yang 2010; Chatterjee, 2012; 
Neumann 2012), there are no published analyses to date that specifically identify 
the focus of promotional claim violations from 2009-2013. METHODS: Warning let-
ters for promotional materials issued by the FDA to pharmaceutical manufacturers 
from 2009-2013 were downloaded and assessed by two investigators for misleading 
claims broadly classified clinical, quality of life (QoL), and economic. Clinical claim 
violations were then stratified according to the following categories: unsubstanti-
ated efficacy, safety and tolerability, superiority, broadening of indication and/or 
omission of risk information. QoL claims categories included unsubstantiated and/
or health-related (HRQoL). Economic claim categories included cost superiority/ 
savings of one drug compared to another. RESULTS: In the 5-year study period, 178 
